For a patient with prostate cancer diagnosed on biopsy with cancer in 2 of 7 cores, each involving about 4% of the core, Gleason score 3 + 4 (Grade Group 2), clinical stage T1c, and prostate-specific antigen below 10 ng/mL, what is the recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Active Surveillance is Appropriate for This Patient

For a patient with Gleason 3+4 (Grade Group 2) prostate cancer involving 2 of 7 cores with only 4% involvement per core, PSA <10 ng/mL, and clinical stage T1c, active surveillance should be offered as the primary management strategy. This patient meets the favorable criteria outlined in current guidelines for selected Grade Group 2 disease 1.

Risk Stratification

This patient has favorable intermediate-risk disease with multiple low-risk features:

  • Only 2 positive cores (≤3 cores)
  • Minimal cancer involvement (4% per core, well below the 50% threshold)
  • PSA <10 ng/mL
  • Clinical stage T1c (not palpable)

The 2024 EAU guidelines specifically state to "offer AS to selected patients with ISUP grade group 2 disease (eg, <10% pattern 4, PSA <10 ng/ml, cT2a, low disease extent on imaging, and low extent of tumour in biopsies, ≤3 positive cores with Gleason score 3 + 4, and ≤50% cancer involvement/core)" 1. This patient fits these criteria precisely.

Critical Next Steps Before Finalizing Active Surveillance

1. MRI Evaluation (Mandatory)

Obtain prostate MRI if not already performed. The PI-RADS score significantly impacts risk stratification:

  • PI-RADS 1-3: Lower risk, stronger AS candidate
  • PI-RADS 4-5 without extraprostatic extension: Moderate risk, still AS candidate
  • Evidence of extraprostatic extension on MRI: Exclude from AS 2

2. Quantify Gleason Pattern 4

The total length of Gleason pattern 4 across all cores is the most predictive metric 3. With 4% involvement in 2 cores, this patient likely has minimal pattern 4 (approximately 1-2mm total if standard 20mm cores), which is highly favorable. Recent data shows that patients with <15% maximum core involvement and low total pattern 4 length have significantly lower upgrading rates 4, 2.

3. Confirmatory Biopsy Strategy

  • If no prior MRI was performed before initial biopsy: Obtain MRI first, then perform confirmatory biopsy with both targeted (any PI-RADS ≥3 lesions) and systematic sampling 1
  • If upfront MRI with targeted + systematic biopsies were already done: No confirmatory biopsy needed 1
  • If MRI unavailable: Perform systematic confirmatory biopsy 1

Recent 2025 data shows 21% of Grade Group 2 patients downgrade to Grade Group 1 and 8% show no cancer on confirmatory biopsy, particularly those with minimal pattern 4 and non-suspicious MRI 2.

Absolute Exclusion Criteria for Active Surveillance

Do not proceed with AS if:

  • Cribriform or intraductal histology present on biopsy 1 (strong recommendation)
  • Upgrading to Grade Group 3 or higher on confirmatory biopsy 1
  • Extraprostatic extension visible on MRI 2

Active Surveillance Protocol

Once confirmed eligible:

  • Repeat biopsies: At least every 3 years for 10 years 1
  • PSA monitoring: Regular intervals (typically every 3-6 months)
  • MRI surveillance: Monitor for changes in imaging
  • Trigger for intervention: PSA progression, DRE changes, or MRI progression should prompt repeat biopsy before proceeding to treatment 1

Reclassification Criteria During Surveillance

Exit AS if repeat biopsies show:

  • 3 positive cores with Grade Group 2

  • 50% cancer involvement per core

  • Any Grade Group 3 or higher disease 1

Alternative Definitive Treatment Options

If the patient declines AS or becomes ineligible, offer:

Radical Prostatectomy (for life expectancy >10 years) 1:

  • Nerve-sparing approach if low risk of extracapsular disease
  • Can be safely delayed 3+ months if needed

Radiation Therapy Options 1:

  • IMRT/VMAT + IGRT (76-78 Gy or moderate hypofractionation) + short-term ADT (4-6 months)
  • LDR brachytherapy (if good urinary function and favorable intermediate-risk)
  • Ultrahypofractionated IMRT/SBRT

Important Caveats

Pattern 4 percentage matters: While guidelines mention <10% pattern 4 as favorable, the total length of pattern 4 is more predictive than percentage 3. With only 4% involvement in 2 cores, this patient has minimal pattern 4 burden.

Individual core grading: If the two positive cores came from the same biopsy site but showed different grades (e.g., one GG2, one GG1), individual scoring may provide better risk stratification than global scoring 5. Clarify this with pathology if applicable.

Watchful waiting vs. Active Surveillance: Reserve watchful waiting (palliative intent) only for patients with life expectancy <10 years 1. This patient requires active surveillance with curative intent if life expectancy >10 years.

References

Related Questions

What is the appropriate next step in management for a patient with bilateral prostate adenocarcinoma involving 7 of 10 biopsy cores, including two cores with Gleason 3+4=7 (grade group 2) and up to 29% tumor involvement?
For a patient with bilateral prostate adenocarcinoma involving 7 of 10 cores (possibly 8), Grade Group 2 (Gleason 3 + 4 = 7) with pattern 4 in two left‑side cores and immunohistochemistry positive for PIN4, p63, high‑molecular‑weight keratin and negative for AMACR, what is the optimal definitive management?
If active surveillance is chosen for a patient with Gleason 3+4 low‑volume prostate cancer, what is the likelihood that the same definitive treatment options (radical prostatectomy or definitive radiation therapy) remain appropriate if disease progression is detected?
What are the next steps in management for a patient with Gleason 7 (3+4) prostate adenocarcinoma involving 4% of biopsy cores?
For a patient with a prostate biopsy showing a positive core but a Gleason grade other than 6, what is the recommended management?
What are the indications for PET-CT in a patient with Gleason 7 (3+4) prostate adenocarcinoma?
What is the most appropriate initial test for a 48-year-old man with three months of bulky, oily, pale stools, mild postprandial upper abdominal pain, recent weight loss, hypertension, hyperlipidemia on lisinopril and atorvastatin, who smokes half a pack daily and drinks about 10 cans of beer per day?
In a 56-year-old woman with a history of polycystic kidney disease, hypertension, and a kidney transplant two years ago (on tacrolimus, prednisone, and mycophenolate), who presents with a 4 mm hard red nodule with ulceration on the left side of the nose persisting for six months, what is the most likely diagnosis?
Which urinary‑tract infection pathogens are susceptible to ciprofloxacin but not to fosfomycin?
For a 32-year-old male veteran with PTSD and a history of substance‑use disorder in remission who presents with worsening insomnia, irritability, and difficulty concentrating after his medication ran out, which pharmacologic agent should be initiated to most effectively relieve his symptoms?
In a 49-year-old woman with non‑ischemic cardiomyopathy and reduced ejection fraction presenting with acute decompensated heart failure, tachycardia, low‑normal blood pressure, elevated NT‑proBNP and volume overload, which intravenous medication is most appropriate: amiodarone, diltiazem, furosemide, or nitroprusside?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.